3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
9
Withdrawn
1
Terminated
1
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Hepatocellular
9
Stomach Neoplasms
5
Triple Negative Breast Neoplasms
3
Liver Neoplasms
3
Breast Neoplasms
3
Small Cell Lung Carcinoma
2
Nasopharyngeal Carcinoma
2
Gastrointestinal Stromal Tumors
2
Esophageal Squamous Cell Carcinoma
2
Cholangiocarcinoma
2
Biliary Tract Neoplasms
2
Adrenocortical Carcinoma
2
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Cancer Limited Stage
1
Small Cell Lung Cancer Extensive Stage
1
Sarcoma
1
Salivary Gland Neoplasms
1
SCLC
1
Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasm Metastasis
1
Meningioma
1
Melanoma
1
Malignant Neoplasms of Digestive Organs
1
Locally Advanced Thyroid Gland Carcinoma
1
Immunotherapy Gastrict Cancer
1
HER2-negative Breast Cancer Brain Metastases
1
Gestational Trophoblastic Disease
1
Interventions
Doxorubicin
15
pembrolizumab
12
Cyclophosphamide
9
Surgical Procedures, Operative
8
Gemcitabine
8
Blood Specimen Collection
8
Ifosfamide
7
Surveys and Questionnaires
6
Nivolumab
6
Trabectedin
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Drug Therapy
5
fludarabine
4
Temozolomide
4
Specimen Handling
4
Radiation Dose Hypofractionation
4
Biopsy
4
selinexor
3
pazopanib
3
liposomal doxorubicin
3
cabozantinib
3
atezolizumab
3
anlotinib
3
Radiation
3
Observation
3
Docetaxel
3
Dacarbazine
3
trastuzumab deruxtecan
2
toripalimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Sarcoma
×
apatinib
×
Clear all
NCT04072042
2025-05-14
BIOVAS
Ruijin Hospital
Phase 2
Recruiting
30 enrolled